Home › Research › Tau biomarkers
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
the Dominantly Inherited Alzheimer Network, Nicolas R. Barthélemy, Yan Li, Nelly Joseph‐Mathurin, Brian Andrew Gordon, Jason J. Hassenstab, Tammie L.S. Benzinger, Virginia Buckles, Anne M. Fagan, Richard J. Perrin, Alison Goate, John C. Morris, Celeste M M. Karch, Chengjie Xiong, Ricardo Allegri, Patricio Chrem Méndez, Sarah B. Berman, Takeshi Ikeuchi, Hiroshi Mori, Hiroyuki Shimada, Mikio Shoji, Kazushi Suzuki, James McC. Noble, Martin Rhys Farlow, Jasmeer P. Chhatwal, Neill R. Graff‐Radford, Stephen Salloway, Peter R. Schofield, Colin Louis Masters, Ralph Nigel Martins, Antoinette O’Connor, Nick C. Fox, Johannes Levin, Mathias Jucker, Audrey Gabelle, Sylvain Lehmann, Chihiro Sato, Randall John Bateman, Randall J. Bateman, Eric McDade. Nature Medicine, 2020-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Researchers quantified the phosphorylation state at multiple sites of the tau protein in cerebrospinal fluid markers across four decades of disease progression in dominantly inherited Alzheimer's disease. They identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over time. These findings provide insights into the pathways linking tau, amyloid-β and neurodegeneration, and may facilitate clinical trials of tau-based treatments.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph‐Mathurin, N., Gordon, B. A., Hassenstab, J. J., et al. (2020). A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nature Medicine. https://doi.org/10.1038/s41591-020-0781-z
Vancouver
the Dominantly Inherited Alzheimer Network, Barthélemy NR, Li Y, Joseph‐Mathurin N, Gordon BA, Hassenstab JJ, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nature Medicine. 2020. doi:10.1038/s41591-020-0781-z. PMID: 32161412.
BibTeX
@article{study2020-32161412,
author = {{the Dominantly Inherited Alzheimer Network} and Barthélemy, Nicolas R. and Li, Yan and Joseph‐Mathurin, Nelly and Gordon, Brian Andrew and Hassenstab, Jason J. and Benzinger, Tammie L.S. and Buckles, Virginia and Fagan, Anne M. and Perrin, Richard J. and Goate, Alison and Morris, John C. and Karch, Celeste M M. and Xiong, Chengjie and Allegri, Ricardo and Méndez, Patricio Chrem and Berman, Sarah B. and Ikeuchi, Takeshi and Mori, Hiroshi and Shimada, Hiroyuki and Shoji, Mikio and Suzuki, Kazushi and Noble, James McC. and Farlow, Martin Rhys and Chhatwal, Jasmeer P. and Graff‐Radford, Neill R. and Salloway, Stephen and Schofield, Peter R. and Masters, Colin Louis and Martins, Ralph Nigel and O’Connor, Antoinette and Fox, Nick C. and Levin, Johannes and Jucker, Mathias and Gabelle, Audrey and Lehmann, Sylvain and Sato, Chihiro and Bateman, Randall John and Bateman, Randall J. and McDade, Eric},
title = {{A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease}},
journal = {Nature Medicine},
year = {2020},
doi = {10.1038/s41591-020-0781-z},
pmid = {32161412},
url = {https://doi.org/10.1038/s41591-020-0781-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 40 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- We identified a pattern of tau staging where site-specific phosphorylation changes occur at different periods of disease progression and follow distinct trajectories over time.
- These tau phosphorylation state changes are uniquely associated with structural, metabolic, neurodegenerative and clinical markers of disease, and some (p-tau217 and p-tau181) begin with the initial increases in aggregate amyloid-β as early as two decades before the development of aggregated tau pathology.
- Others (p-tau205 and t-tau) increase with atrophy and hypometabolism closer to symptom onset.
Why it matters
Reports a signature of soluble phosphorylated tau that links tau, amyloid and the stages of dominantly inherited Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
How this study scored 63/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 60 of the 95 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature Medicine) |
| Journal's citation record | 4 / 4 | Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 649 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 81.1 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 6 / 6 | Cited 44.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 299 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Eric McDade: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 29 institution(s) in 7 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32161412) |
| Free to read | 2 / 2 | Free to read |
| Points | 60 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 60 of the 95 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.